Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

 Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19

Shots:

  • Merck to receive ~$1.2B to supply ~1.7M courses of molnupiravir to the US government, if its receives EUA or approval from the US FDA and expects to have 10M+ courses of therapy available by the end of 2021
  • The therapy is currently being evaluated in a P-III MOVe-OUT study in non-hospitalized patients with COVID-19. Merck also plans to file for EUA or approval outside the US
  • Merck is collaborated with generic manufacturers to accelerate the availability of the therapy in 104 LMICs, following the approvals or EUA by local regulatory agencies & plans to initiate a clinical program of molnupiravir for post-exposure prophylaxis in H2’21

Click here to­ read full press release/ article | Ref: Business Wire | Image: Spagnola & Associates

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post